| Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. | |
| | |
MedLine Citation:
|
PMID: 12198224 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The mortality rate is high among end-stage renal disease (ESRD) patients, and recent evidence suggests that this may be linked to inflammation. The activity of interleukin-6 (IL-6) and its soluble receptor (sIL-6R) are markedly up-regulated in ESRD patients, and plasma IL-6 levels predict outcome in haemodialysis (HD) patients. However, it has not been established whether elevated plasma IL-6 also predicts outcome in ESRD patients treated by peritoneal dialysis (PD), and how it relates to the data on HD patients. The predictive power of sIL-6R levels on outcome is also unknown in this patient population. METHODS: To determine whether or not plasma IL-6 and sIL-6R predict patient survival, we studied 173 ESRD patients (62% males, 53+/-1 years of age) near the initiation of dialysis treatment (99 PD, 74 HD patients). The patients were followed for a mean period of 3.1+/-0.1 years (range 0.1-7.1 years) and were stratified at the start of dialysis treatment according to age, gender, presence of cardiovascular disease, malnutrition (determined by subjective global assessment), diabetes mellitus, and IL-6 and sIL-6R plasma levels. RESULTS: A significantly different (P<0.0001) mortality rate was observed in different groups when patients were divided into quartiles according to IL-6 levels. Furthermore, the same differences were observed, less notably however, for sIL-6R (P<0.05). When patients were stratified according to IL-6 quartiles and analysed separately according to the different initial treatment groups, a similar profile of survival was observed for PD (P<0.01) and HD (P<0.05) patients. In a Cox proportional hazard model adjusting for the impact of age, malnutrition, diabetes mellitus and male gender, log IL-6 values were independently associated with poor outcome (P<0.05). CONCLUSIONS: The present study demonstrates that the strong predictive value of elevated IL-6 levels for poor outcome in ESRD patients is similar in both HD and PD patients starting treatment. |
| | |
Authors:
|
Roberto Pecoits-Filho; Peter Bárány; Bengt Lindholm; Olof Heimbürger; Peter Stenvinkel |
Related Documents
:
|
20535794 - Clinical relevance of persistently elevated circulating cytokines (tumor necrosis facto... 14636754 - Examination of soluble fas (sfas) and soluble fas ligand (sfasl) in patients with burns. 7959354 - Coagulation/fibrinolysis balance in septic shock related to cytokines and clinical state. 17420794 - Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with i... 6709824 - Tuberculosis of the central nervous system. 287464 - Tracheobronchopathia osteochondroplastica. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association Volume: 17 ISSN: 0931-0509 ISO Abbreviation: Nephrol. Dial. Transplant. Publication Date: 2002 Sep |
Date Detail:
|
Created Date: 2002-08-28 Completed Date: 2003-02-12 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8706402 Medline TA: Nephrol Dial Transplant Country: England |
Other Details:
|
Languages: eng Pagination: 1684-8 Citation Subset: IM |
Affiliation:
|
Division of Renal Medicine, Department of Clinical Science, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden. roberto.pecoits-filho@klinvet.ki.se |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biological Markers
/
blood Female Humans Interleukin-6 / blood* Kidney Failure, Chronic / immunology, mortality, therapy* Male Middle Aged Peritoneal Dialysis / mortality* Predictive Value of Tests Proportional Hazards Models Receptors, Interleukin-6 / blood Renal Dialysis / mortality* Survival Rate Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Interleukin-6; 0/Receptors, Interleukin-6 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Kidney transplantation in type 2 diabetic patients: a comparison with matched non-diabetic subjects.
Next Document: Glucocorticoid receptors in hippocampal neurons that do not engage proteasomes escape from hormone-d...